Abstract: Cyclosporin A is a kind of calcineurin inhibitor, which is often used for the prevention of immune rejection after transplantation and the treatment of aplastic anemia, rheumatoid arthritis, nephrotic syndrome and other diseases. It has a narrow therapeutic window, with many factors affecting its pharmacokinetic process. The pharmacokinetic process varies greatly among individuals, so it is necessary to implement individualized dosage regimens in clinical practice. Population pharmacokinetics establishes the population value model of pharmacokinetic parameters using nonlinear mixed effect model to quantitatively investigate the effects of demographic characteristics, genetic factors and drug combination on pharmacokinetic parameters, which play an important role in personalized medicine. This paper reviews the pharmacokinetic characteristics of cyclosporin A and the progress in population pharmacokinetic studies, and analyzes the possible factors affecting the pharmacokinetic process, in order to provide some reference for the design of individualized dosage regimens of cyclosporin A in clinical practice.